Stockscreener 앱 받기
163.80
0.41%
-0.67
시간 외 거래:
162.80
-1.00
-0.61%
전일 마감가:
$164.47
열려 있는:
$164.31
하루 거래량:
1.49M
Relative Volume:
1.21
시가총액:
$18.64B
수익:
$9.54B
순이익/손실:
$841.00M
주가수익비율:
22.02
EPS:
7.44
순현금흐름:
$1.02B
1주 성능:
-0.03%
1개월 성능:
-5.58%
6개월 성능:
+9.96%
1년 성능:
+29.00%
1일 변동 폭
$162.47
$165.59
1주일 범위
$161.60
$169.69
52주 변동 폭
$125.42
$178.87
퀘스트 다이아그노스틱스 Stock (DGX) Company Profile
명칭
Quest Diagnostics Inc
전화
(973) 520-2700
주소
500 PLAZA DRIVE, SECAUCUS
DGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
163.80 | 18.64B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
427.50 | 169.62B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
186.83 | 138.06B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
411.49 | 32.79B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
102.48 | 29.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
143.91 | 26.61B | 15.41B | 1.37B | 2.11B | 7.50 |
퀘스트 다이아그노스틱스 Stock (DGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Redburn Atlantic | Buy |
| 2025-03-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | Jefferies | Buy |
| 2024-10-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | 재개 | Evercore ISI | In-line |
| 2024-07-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 개시 | Barclays | Equal Weight |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-06-29 | 개시 | Piper Sandler | Neutral |
| 2023-05-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-04-03 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-23 | 개시 | Evercore ISI | In-line |
| 2022-11-17 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-08-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-04-04 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-02-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-01-28 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-05-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-03-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | 업그레이드 | Argus | Hold → Buy |
| 2020-07-29 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-09 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-04-28 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-04-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | 개시 | Wells Fargo | Underweight |
| 2020-01-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-12-19 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-04-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-03-18 | 재개 | Credit Suisse | Neutral |
| 2019-01-31 | 다운그레이드 | Argus | Buy → Hold |
| 2019-01-17 | 개시 | UBS | Neutral |
| 2019-01-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
퀘스트 다이아그노스틱스 주식(DGX)의 최신 뉴스
Drug Screening Market Size Worth USD 10.34 Billion by 2034 | CAGR of 4.84% from 2025 to 2034 - GlobeNewswire Inc.
Peering Into Quest Diagnostics's Recent Short Interest - Benzinga
Price Over Earnings Overview: Quest Diagnostics - Benzinga
Quest Diagnostics price target raised to $198 from $190 at BofA - Yahoo Finance
Quest Diagnostics (DGX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Here's How Quest Diagnostics is Placed Ahead of Q1 Earnings - TradingView
Quest Diagnostics (DGX): Price Target Increased to $198 by BofA Analyst | DGX Stock News - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Declares Quarterly Cash Dividend - Quantisnow
Quest introduces blood test to confirm amyloid brain pathology in Alzheimer’s - Medical Device Network
Quest Diagnostics (NYSE:DGX) Unveils New Alzheimer's Blood Test With Promising Predictive Accuracy - Yahoo Finance
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease - PR Newswire
Revolutionary Blood Test Transforms Alzheimer's Diagnosis: Quest's New 91%-Accurate Solution - Stock Titan
Here's What to Expect From Quest Diagnostics’ Next Earnings Report - MSN
Quest Diagnostics : To Speak At The 38th Annual J.P. Morgan Healthcare Conference - MarketScreener
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Compensation Up For Quest Diagnostics GC After Earlier Dip - Law360
Quest Diagnostics (DGX) Shares Cross 2% Yield Mark - Nasdaq
Here's What To Expect From Quest Diagnostics’ Next Earnings Report - Barchart.com
Lobbying Update: $80,000 of QUEST DIAGNOSTICS INCORPORATED lobbying was just disclosed - Nasdaq
Quest Diagnostics CEO sells $6.6 million in stock By Investing.com - Investing.com South Africa
Quest Diagnostics CEO sells $6.6 million in stock - Investing.com
Quest Diagnostics SVP Karthik sells $434,350 in stock By Investing.com - Investing.com Canada
Quest Diagnostics SVP Karthik sells $434,350 in stock - Investing.com
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80 - Yahoo Finance
Ex-Dividend Reminder: Quest Diagnostics, Preferred Bank and Erie Indemnity - Nasdaq
Redburn Atlantic Initiates Quest Diagnostics at Buy With $195 Price Target - MarketScreener
Quest Diagnostics Incorporated (NYSE:DGX) Passed Our Checks, And It's About To Pay A US$0.80 Dividend - Yahoo
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target - Quantisnow
Quest Revolutionizes Cervical Cancer Screening with New Self-Collection Test - Stock Titan
Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025 - Nasdaq
Quest Diagnostics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan
Quest Health Review 2025: Services, Pricing, and Reliability - Healthline
Quest Diagnostics Incorporated (NYSE:DGX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Is Quest Diagnostics Stock Outperforming the S&P 500? - MSN
SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 162 shares, decreasing direct ownership by 0.77% to 20,988 units (SEC Form 4) - Quantisnow
Is Quest Diagnostics Stock Worth Holding Onto Right Now? - MSN
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target - Marketscreener.com
Is Quest Diagnostics Stock Outperforming The S&P 500? - Barchart.com
Truist maintains hold on Quest Diagnostics stock, $182 target By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI - Insider Monkey
DGX Stock Set to Benefit From New Google Cloud Partnership - MSN
Top 8 AI News Updates Investors Shouldn’t Miss - Insider Monkey
What 9 Analyst Ratings Have To Say About Quest Diagnostics - Benzinga
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance - AlphaStreet
Baird Adjusts Price Target on Quest Diagnostics to $191 From $190, Keeps Outperform Rating - Marketscreener.com
퀘스트 다이아그노스틱스 (DGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
퀘스트 다이아그노스틱스 주식 (DGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Apr 02 '25 |
Sale |
170.00 |
2,555 |
434,350 |
10,575 |
1.56%
자본화:
|
볼륨(24시간):